retatrutide efficacy clinical trials and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 retatrutide clinical trials safety efficacy

These effects form the foundation of incretin-based obesity therapy and have been studied extensively since semaglutides approval in 2017

In a longitudinal study of such patients, mean pro-C3 increased with worsening of fibrosis and decreased with fibrosis improvement 36

For a detailed head-to-head comparison, see our retatrutide vs tirzepatide comparison guide

Clin Ther (2012) 34:208290

These symptoms can overlap with and potentially worsen the gastrointestinal effects already associated with GLP-1 therapy, making it difficult to distinguish which agent is responsible for adverse effects

A replacement ships on the next run